Prophylactic somatostatin can reduce incidence of post-ERCP pancreatitis: multicenter randomized controlled trial

Volume: 47, Issue: 05, Pages: 415 - 420
Published: Jan 15, 2015
Abstract
Background and study aim: Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) remains the most common complication of ERCP. Somatostatin may inhibit pancreatic secretion and has been tested for PEP prophylaxis. However, the results of previous studies are inconsistent. The aim of the current study was to investigate whether somatostatin can reduce the incidence of PEP. Patients and methods: The study was a...
Paper Details
Title
Prophylactic somatostatin can reduce incidence of post-ERCP pancreatitis: multicenter randomized controlled trial
Published Date
Jan 15, 2015
Journal
Volume
47
Issue
05
Pages
415 - 420
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.